Antibody

The Novus Product Development Team is excited to announce the launch of a new antibody target not currently available by any other antibody suppliers. The two new antibodies, a human TMEM97 antibody (NBP1-30436) and mouse TMEM97 antibody (NBP1-30437) are of particular interest as TMEM97 is implicated in several cancers, including breast, pancreatic, colorectal and ovarian cancers.

Recent antibody studies have suggested that nuclear factor κB-inducing kinase (NIK) is inhibited through proteasome-controlled degradation regulated by TRAF/cIAP proteins. cIAP1 and cIAP2 are fairly recent apoptosis inhibitors and represent some of the newer products in our antibody catalog.

MAPK (mitogen-activated protein kinase) antibodies are widely used in cellular research to study these processes, in both healthy and cancerous cells. For example, p38 is a pro-apoptotic factor, and c-Jun NH2-terminal kinase (JNK) regulates cellular longevity and stress resistance. Together they form the JNK/p38 signaling pathway, which is controlled by at least five MAPK cascades.

We at Novus Biologicals have a huge range of monoclonal and polyclonal immunoglobulins on our antibody database, and are constantly developing more. Immunoglobulins comprise a number of different classes, and it’s important you select the right one for your needs. Here, we give a brief run-down of antibody classification.

Since DNA-damage can lead to the development of tumours, these antibodies are widely used in cancer studies. Cyclin dependent kinases (CDKs), which interact with regulatory cyclins, are essential to the progression of the cell cycle. However, tumours can develop if CDK/cyclin disruption leads to unregulated cell reproduction. Therefore these two proteins are carefully regulated.

Not everybody working in immunobiology has an in-depth knowledge of the subject. Some may be students, who are still getting to grips with the discipline at college. Others may have been forced into a swift career change following restructuring at work. For whatever reason, people quite often perform their first antibody assays with only the vaguest knowledge of the underlying concepts.

IgG is the most prevalent antibody in mammalian tissue, and therefore a major number of the proteins on an antibody database are of this type. The other classes that are studied are IgA, IgM, IgD and IgE. Depending on the tissue and disease being studied, polyclonal and monoclonal versions of all these antibodies are also produced against specific antigens.

In the body, plasma B-cells produce large numbers of antibodies specific to foreign proteins. In the 1970s, studies into multiple myeloma (a B-cell cancer) revealed these plasma cells produced an antibody specific to one protein. This led to development of other antigen-specific antibodies.

Many people enter immunobiology from a different area of research. Although they swiftly learn the protocols and methods of the assays, they may not fully understand the underlying concepts. We at Novus Biologicals realise that not everybody purchasing products from our antibody catalogue has an in-depth knowledge of the “tools of the trade”. For them, and anybody else needing a quick bit of revision, we have put together a few basic notes.

Tumour Necrosis Factor Receptor 2 (TNFR2) exists as both a cytoplasmic and transmembrane glycoprotein. Together with TNFR1, it has been shown to stimulate T lymphocyte activity via TNFα action. The TNF signalling pathways are complex, and mutation or disruption of the proteins at any stage can cause oncogenesis. Therefore TNF-related antibodies are widely used in immunoassays for cancer research.